FY26 consensus $14.51. Raises FY26 reported revenue growth view to 8.6%-10.6% and CAG Diagnostics recurring revenue reported growth of 9.6%-11.6%, with projected 2026 organic revenue growth of 7.7%-9.7% and CAG Diagnostics recurring revenue organic growth of 8.7%-10.7%. FY26 consensus $4.68B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDXX Upcoming Earnings Report: What to Expect?
- Idexx Laboratories price target lowered to $640 from $730 at UBS
- Cloudflare upgraded, SolarEdge downgraded: Wall Street’s top analyst calls
- Idexx Laboratories initiated with a Neutral at Citi
- Idexx Laboratories announces Idexx Cancer Dx Panel availability in the UK